Cipla Limited recorded ₹ 1,298 crore with a 10.2 percent year-on-air growth in the consolidated net profit for the first quarter of FY26. Revenue rose 4 percent to ₹ 6,957 crore, with a strong Ebitda margin of 25.6 percent.
| scale | Q1 FY26 | Q1 FY25 | Yoy growth |
|---|---|---|---|
| Total income from operations | 6,957 | 6,694 | 3.9 percent |
| Ebitda | 1,778 | 1,716 | 3.6 percent |
| Percentage of income from operations | 25.6 percent | 25.6 percent | -7 bps |
| PAT | 1,298 | 1,178 | 10.2 Percentage |
financial performance
The results of CIPLA’s Q1 FY26 reflect the speed of continuous profitability by being inspired by strong performance in major markets. The company’s Ebitda margin remained strong at 25.6 percent.
Business Segment Highlights
- One-India: One-India business increased by 6 percent YOY, which crossed ₹ 3,000 crore for the first time in the early quarter of any financial year.
- North America: North America raised a quarterly quarterly revenue in differentiated assets. The company launched Nano Paclitaxel Vicle (Anda) and Nilotinib Capsule (NDA).
- Forest Africa: In the context of the USD, the speed of growth continued with the overall revenue increase of 11 percent YOY. Prescription business was at number 2 in the market.
- Emerging Markets and Europe: These markets recorded a healthy revenue increase of 8 percent in terms of USD.
R&D Investment and Net Cash Position
Cipla’s R&D investment was ₹ 432 crore, which is 6.2 percent of sales inspired by product filing and development efforts. The company maintained a strong net cash position of ₹ 10,379 crore, including the loan mainly lease liabilities and working capital requirements.
Segment-wise sales performance
The table below shows Yoy Sales Performance in various business segments:
| Business | Q1 FY26 | Q1 FY25 | Growth |
|---|---|---|---|
| India (RX + GX + CHLA) | 3,070 | 2,898 | 6 percent |
| North america | 1,933 | 2,087 | -7 percent |
| Forest Africa | 871 | 766 | 14 percent |
| South Africa | 695 | 626 | 11 percent |
| Emerging Markets and Europe | 861 | 779 | 11 percent |
| API | 102 | 98 | 3 percent |
| Other | 121 | 65 | 85 per cent |
| Total | 6,957 | 6,694 | 4 Percentate |
Market update
- One India Business: The major therapy in the branded prescription business continued to overtake the market growth. Trade generics recorded a strong growth, launching 7 new products in Q1 FY26. Consumer Health Anchor Brands maintained leadership positions.
- North America: Albetherol was at number 1 in the overall American Albuterol MDI market with a 19.5 percent market share. Lamriotide also performed well, which reached 21 percent market share during the quarter.
- Forest Africa: The USD recorded a strong growth of 11 percent. The overall private market of South Africa stood at number 3 in the market, while the prescription business retained its number 2 position.
- Emerging Markets and Europe: Both the DTM and B2B categories recorded an 8 percent increase in the reference to the USD, as well as the overall margin.
Management commentary
Commenting on the results, Cipla Ltd’s MD and Global CEO Umang Vohra said, “I am happy to say that we are constantly making significant progress in our focus markets. In Q1Fy26, we gave a stable Revenue of INR 6,957 crore with a healthy ebitda margin of 25.6 percent. Strengthening, investing in future pipelines, as well as focusing on solutions on the regulatory front will be on. “